- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01517828
Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room
Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room.
Anesthesia is rarely used to intubate newborns in delivery room because of the very difficulty of accessing veins. The investigators hypothesized that intranasal administration of sedative would be an effective alternative. -Midazolam and Ketamine are two drugs used during neonates' intubation. They are also used intranasally in the absence of venous access-In a pilot study the investigators have demonstrated that sedation with Midazolam was effective in 67% of the patients. Efficiency was defined by a specific pain score: FANS < 4 (Faceless Acute Neonatal Pain Scale) and by an impedancemetric Pain monitor < 0.2 spike/s.
The investigators hypothesized that intranasal ketamine would increase procedure effectiveness from 67 to 90%.
- Main objective: To compare newborns sedation quality as they are sedated either by intranasal Midazolam or by intranasal Ketamine during intubation in delivery room.
- Secondary Objectives: To compare intubation quality, hemodynamic and respiratory tolerance, and neurological outcomeat 2 years within the two groups.
Study Overview
Status
Intervention / Treatment
Detailed Description
Randomized, double blind prospective multicenter study. Patients:-Inclusion criteria: (1) neonates in delivery room (2) Presence of repiratory distress syndrom requiring intubation (Silverman score> 3 and / or FiO2 greater than 30 % in premature infants under 30 weeks and over 40% after 30 weeks (3) hemodynamic stability (mean arterial pressure> 3° percentile)
- Exclusion criteria: (1) Need for intubation in extreme emergency (pneumothorax, meconium aspiration, congenital diaphragmatic hernia, perinatal asphyxia) (2) Birth in the absence of an independent appraiser (3) mother under general anesthesia.
- Number of subjects required: 120 patients (60 per group) over a period of two years. This number was calculated to show a difference in sedation effectiveness from 67 to 90% with an alpha risk of 5% and a beta risk of 20%.
- Study design:
After obtaining parental consent, patients will be randomized in "Midazolam" arm or in "Ketamine" arm . Midazolam (0.2mg/kg = 0.2ml/kg) or Ketamine (2mg/kg = 0.2 ml/kg) are instilled in the nose, using a 1 ml syringe. The gesture will be directed by a physician having yet successfully completed a minimum of 50 intubations. After sedation completion, intubation decision will be taken at the onset of muscle relaxation or on the occurrence of apnea.
- The clinical pain score will be evaluated on film a posteriori by two independent observers using a scale of hetero pain assessment.-Pain will be evaluated through the study of skin conductance.
- The quality of intubation will be judged by the number of attempts required and by the duration of glottis exposure.
- Hemodynamic and respiratory tolerances will be judged by measuring respectively variations in blood pressure, heart rate, FiO2 and the oxygen saturation.
The neurological follow-up will be carried out according to Brunet-Lezine developmental scale at the age of 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34000
- Centre Hospitalier Universitaire
-
Nimes, France, 30000
- Centre Hospitalier Universitaire
-
Perpignan, France, 66000
- Centre Hospitalier General
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neonates in delivery room
- Presence of respiratory distress syndrom requiring intubation (Silverman score> 3 and / or FiO2 greater than 30 % in premature infants under 30 weeks and over 40% after 30 weeks
- Hemodynamic stability (mean arterial pressure> 3° percentile)
Exclusion Criteria:
- Need for intubation in extreme emergency (pneumothorax, meconium aspiration, congenital diaphragmatic hernia, perinatal asphyxia)
- Birth in the absence of an independent appraiser
- Mother under general anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketamine Arm
Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
|
Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts. One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done. |
Active Comparator: Midazolam Arm
Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
|
Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties. One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Newborns sedation quality
Time Frame: during the 10 minutes of intubation
|
The sedation quality of 2 newborns groups will be compared during the 10 minutes of intubation directly in delivery room and after on the film Pain evaluation done by a Specific clinical Score : the Faceless Acute Neonatal pain Scale (FANS) noted by two independent professional persons.
And for Montpellier center, evaluation of pain by cutaneous conductance
|
during the 10 minutes of intubation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intubation quality
Time Frame: during the 10 minutes of intubation
|
Intubation quality will be evaluated and compared between the two groups by numbers of attempts, duration of glottis exposition (from introduction to withdrawal of laryngoscop)
|
during the 10 minutes of intubation
|
hemodynamic and respiratory tolerance
Time Frame: during 24 hours after intubation
|
Hemodynamic tolerance will be measured by Mean Arterial Pressure every 3 minutes before and after product instillation and during the intubation. After intubation, measure of Mean Arterial Pressure will be done every 10 minutes during 1 hour and after every hour until 24 hours. Cardiac frequency and cardiac fraquency variations will be measured and analyzed. Respiratory tolerance will be evaluated by continuing measure of SpO2, delay of instillation of surfactant dose and the need to administer un second dose of surfactant |
during 24 hours after intubation
|
neurological outcome at 2 years within the 2 groups
Time Frame: 2 years after the treatment
|
Prevalence of neurological complications (intraventricular hemorragies, periventricular leucomalacies), development quotient at 2 years (Brunet Lezine scale)will be evaluated and compared between the two groups
|
2 years after the treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christophe CM MILESI, MD, University Hospital, Montpellier
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- Infant, Premature, Diseases
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Ketamine
- Midazolam
Other Study ID Numbers
- UF8736
- 2011-003216-23 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Dr Anna Lavizzari; Dr Francesca Gaia CiuffiniCompletedNewborn Respiratory Distress SyndromeItaly
-
Assiut UniversityRecruitingNeonatal Respiratory DistressEgypt
-
Groupe Hospitalier Paris Saint JosephCompletedEarly Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year (DROPE)Neonatal Respiratory Distress SyndromeFrance
-
Karolinska University HospitalCompletedRespiratory Distress Syndrome, Adult | Respiratory Distress Syndrome, ChildSweden
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Respiratory Distress Syndrome ARDS
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Postgraduate Institute of Medical Education and...TerminatedAcute Respiratory Distress Syndrome (ARDS)India
Clinical Trials on Sedation by ketamine
-
Serveis de Salut Integrats Baix EmpordàCompletedColo-rectal Cancer | Colon Adenoma | ADR
-
Tampa General HospitalWithdrawnEffect of Protocolized Sedation on Days of Mechanical Ventilation in the ICUUnited States
-
Universidad de ColimaInstituto Mexicano del Seguro SocialRecruiting
-
Centre Hospitalier Universitaire de NiceCompletedFracture | DislocationFrance
-
University of ChileWithdrawnMechanical Ventilation | Deep SedationChile
-
Hospital Italiano de Buenos AiresActive, not recruitingDelirium | Sedative OverdoseArgentina
-
Memorial Medical CenterTerminatedRespiratory InsufficiencyUnited States
-
Virginia Commonwealth UniversityNational Institutes of Health (NIH); American Lung AssociationTerminatedDepression | Quality of Life | Sedation | Post-traumatic Stress Disorder | Mechanical Ventilation
-
Hospital Beatriz ÂngeloCompletedDigestive System Diseases | Colonoscopy SedationPortugal
-
Poitiers University HospitalCompletedFracture | Dislocation | Reality Device | Reduction ProcedureFrance